Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, announced Michael L. Capone is joining the company as chief operating officer COO. In the newly created COO role, he will report directly to Medidata's CEO Tarek Sherif and president Glen de Vries. Capone joins Medidata from ADP, one of the world's largest business-to-business software providers, where he served as corporate vice president of product development and chief information officer.

Capone will play a central role in Medidata's product development, professional services, go-to-market and day-to-day operations—continuing and accelerating Medidata's strategy to provide a comprehensive cloud platform that lowers the cost and risk of clinical trials and speeds new treatments to market.

"This is an exciting time for Medidata, with increasing acknowledgement of the Medidata Clinical Cloud™ as the life sciences' strongest cloud platform," said Sherif. "Mike's leadership in large-scale SaaS software development and his deep operational experience make him the right person to help us seize this moment and scale Medidata to capture the enormous opportunity ahead of us."

"Tarek and I are looking forward to working together with Mike as we continue to grow the business and help our customers bring life-saving and life-enhancing treatments to patients," added de Vries.

As corporate VP and CIO of ADP, a leading provider of human capital management services, Capone led product development and information technology. Under his technology leadership, ADP earned accolades for its innovations, and now serves more than 430,000 clients and 35 million users on its SaaS platforms. Capone is a 25-year veteran of ADP and has held positions in product development, information technology and operations. He earned a BS in computer science from Dickinson College and an MBA in finance from Pace University, and he serves on the board of several non-profit organizations, including the Leukemia and Lymphoma Society.

"Joining Medidata channels my personal passion for medical research into an innovative tech company early in its growth curve," said Capone. "All of the right ingredients are here: a solid business model, leading vertical SaaS platform and loyal customers. I'm eager to jump in and join the team in taking Medidata to the next level.

Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) announced that data on its investigational agent PV-10 for intralesional IL treatment of locally advanced cutaneous melanoma was featured in a poster presentation on Sunday, September 28, 2014 during the European Society For Medical Oncology (ESM0) 2014 Congress in Madrid, Spain. The presentation showed that PV-10 elicits a high rate of response in injected tumors through its ablative effect, and additionally, that the durability of response as well as the bystander response in uninjected tumors implicate an additional immunologic mechanism secondary to ablation.  Link to full release:  Provectus Press Release

The poster, presented by Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University, based upon abstract #1120P, was entitled, "Subgroup Efficacy in Patients Receiving Intralesional Rose Bengal to All Existing Melanoma in Phase II Study PV-10-MM-02." It can be accessed via the following link:  Provectus Publications

Commenting on the poster, Dr. Agarwala said, "Although the primary ablative effect of PV-10 can lead to rapid regression of injected lesions, durability of response may signal the effects of an immunologic process secondary to ablation. In addition to offering the potential to relieve symptoms of cutaneous melanoma, a robust, tumor-specific immunologic response could have the potential of changing the course of the disease."

Eric Wachter, PhD and Chief Technology Officer of Provectus, said, "We are very pleased to share the patient-level PFS data at ESMO that defined our design parameters for the upcoming phase 3 trial. These study results demonstrate the potential of an intralesional approach to delay progression while alleviating symptoms of locally advanced melanoma."